The unlisted firm’s parent Reliance Industries did not immediately respond to a Reuters request for comment.
Reuters
August 26, 2021 / 12:38 PM IST
Representative image
India’s Reliance Life Sciences has applied for regulatory approval to begin early stage human trials of its COVID-19 vaccine candidate, The Economic Times reported on Thursday.
The unlisted firm’s parent Reliance Industries did not immediately respond to a Reuters request for comment.
Disclaimer: “Reliance Industries Ltd. is the sole beneficiary of Independent Media Trust which controls Network18 Media & Investments Ltd.”
Follow our full coverage of the coronavirus pandemic here.
